Andrew J. Klink, PhD, MPH

Articles by Andrew J. Klink, PhD, MPH

Real-World Outcomes Among Patients With Early Rapidly Progressive Rheumatoid Arthritis

ByAndrew J. Klink, PhD, MPH,Tammy G. Curtice, PharmD, MBA, MS,Kiran Gupta, PhD, MPharm,Kenneth W. Tuell, RPh, BCGP,A. Richard Szymialis, RPh,Damion Nero, PhD,Bruce A. Feinberg, DO

This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.

Latest Updated Articles



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text